QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CTMX

QT40CytomX Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
2.95
-0.01-0.34%
OverviewShort InterestFilings
CTMXQT40CytomX Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
2.95-0.34%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
0.50
Insider Own4.07%
Shs Outstand217.70M
Perf Week-1.01%
Market Cap476.04MForward P/E-EPS next Y-0.50Insider Trans-0.09%Shs Float-Perf Month-18.96%
Enterprise Value450.07MPEG0.05EPS next Q-0.11Inst Own-Short Float-Perf Quarter-38.28%
Income-53649443.00P/S13.39EPS this Y-183.13%Inst Trans-Short Ratio-Perf Half Y-30.59%
Sales35.54MP/B1.64EPS next Y-19.39%ROA-16.46%Short Interest-Perf YTD-30.75%
Book/sh0.55P/C-EPS next 5Y-ROE-36.61%52W High8.21 -64.07%Perf Year23.95%
Cash/sh0.73P/FCF-EPS past 3/5Y-ROIC-19.70%52W Low1.72 71.51%Perf 3Y-
Dividend Est.-EV/EBITDA-7.80Sales past 3/5Y12.77% 2.25%Gross Margin99.29%Volatility3.69% 3.45%Perf 5Y-
Dividend TTM-EV/Sales12.66EPS Y/Y TTM-208.21%Oper. Margin-181.92%ATR (14)0.19Perf 10Y-
Dividend Ex-Date-Quick Ratio10.38Sales Y/Y TTM6.52%Profit Margin-166.40%RSI (14)31.02Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.38EPS Q/Q-137.04%SMA20-9.29%Beta1.51Target Price10.71
Payout0.00%Debt/Eq0.01Sales Q/Q-80.39%SMA50-22.77%Rel Volume2.54Prev Close2.96
Employees119LT Debt/Eq-0.19EarningsAug 06SMA200-27.28%Avg Volume3.83MPrice2.95
IPO DateOct 08, 2015Option/ShortNo / YesEPS/Sales Surpr.28.57% 100.00%Net Debt/EBITDA0.45Volume9,732,396Change-0.34%
Analyst Ratings
DateActionAnalystRatingTarget
May-19-26InitiatedWolfe ResearchOutperform$6.00
May-11-26ReiteratedH.C. WainwrightBuy$17 → $11
Mar-18-26ReiteratedJefferiesBuy$8.00 → $16
Mar-16-26ReiteratedOppenheimerPerform$7.00 → $12
Mar-16-26UpgradeJP MorganNeutral → Overweight
Feb-04-26ReiteratedBarclaysOverweight$8.00 → $10
Jan-20-26InitiatedGuggenheimBuy$10
Jan-20-26ReiteratedPiper SandlerOverweight$3.25 → $10
Jan-20-26ReiteratedBarclaysOverweight$6.00 → $8.00
Oct-21-25ReiteratedBarclaysOverweight$3.50 → $6.00
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue14776138
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit14776138
Selling, General and Administrative Excl. Other313030
Research and Development806983
Other Operating Expense000
Operating Income37-2225
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-6-5-7
Net Income Before Taxes43-1732
Income Taxes000
Consolidated Net Income42-1732
Net Income From Continuing Operations42-1732
Net Income42-1732
EPS (Recurring)0.50-0.150.38
EPS (Basic, Before Extraordinaries)0.50-0.150.38
EPS (Diluted)0.50-0.150.38
EBITDA43-1634
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
5.90——
Price To Sales Ratio1.757.74—
Gross Margin100.00100.00100.00
Operating Margin25.17-28.9518.12
Net Margin28.57-22.3723.19
Shares Outstanding8713884
Market Capitalization257588—
Operating Lease Expense
———
Insider Trading Volume
$3.12$2.86$2.59$2.33$2.07● Close Price0.00M0.31M0.61M0.92M1.23MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ogden ChristopherChief Financial OfficerJun 15 '26Sale3.051,6244,953295,324Jun 17 12:00 AM
McCarthy Sean A.CEOMar 17 '26Sale6.42118,969764,1381,078,922Mar 19 12:00 AM
Ogden ChristopherChief Financial OfficerMar 17 '26Sale6.4219,323124,112296,948Mar 19 12:00 AM
Chu Yu-WayeChief Medical OfficerMar 17 '26Sale6.4221,279136,675189,446Mar 19 12:00 AM
BELVIN MARCIASVP, Chief Scientific OfficerMar 17 '26Sale6.4231,492202,273300,760Mar 19 12:00 AM
McCarthy Sean A.CEONov 06 '25Sale4.54101,793461,906987,891Nov 10 12:00 AM
Ogden ChristopherChief Financial OfficerJun 16 '25Sale2.6910,61428,540226,271Jun 17 12:00 AM
BELVIN MARCIASVP, Chief Scientific OfficerJun 16 '25Sale2.6913,88437,334272,252Jun 17 12:00 AM
McCarthy Sean A.CEOJun 16 '25Sale2.6955,511149,2641,089,684Jun 17 12:00 AM
Ogden ChristopherChief Financial OfficerJun 13 '25Option Exercise0.0075,0000236,885Jun 17 12:00 AM
BELVIN MARCIASVP, Chief Scientific OfficerJun 13 '25Option Exercise0.0075,0000286,136Jun 17 12:00 AM
McCarthy Sean A.CEOJun 13 '25Option Exercise0.00300,00001,145,195Jun 17 12:00 AM
Ogden ChristopherChief Financial OfficerJun 13 '25Sale2.951,6414,841199,385Jun 17 12:00 AM
McCarthy Sean A.CEOMar 18 '25Sale0.6037,65622,556995,195Mar 20 12:00 AM
Ogden ChristopherChief Financial OfficerMar 18 '25Sale0.608,5515,122201,026Mar 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR